Editorials

High-risk stays high-risk: Bruton tyrosine kinase inhibitors in B-cell malignancies

University of Cologne, Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Germany; Cancer Institute, University College London, United Kingdom; Francis Crick Institute, London
Haematologica Early view Mar 7, 2024 https://doi.org/10.3324/haematol.2024.285029